YFSA19
100μL
￥320
ICC/IF, IHC-F, FC, ELISA
Background：
|
Yfxbio® secondary antibodies are available conjugated to enzyme, biotin or fluorophore for use in a variety of antibody-based applications including Western Blot, ImmunoHistoChemistry, ImmunoFluorescence, Flow Cytometry and ELISA. We offer high quality secondary antibodies from goat, rabbit and donkey sources for your each application. |
Product Information：
|
Product name: Goat Anti-Mouse IgG (H+L), Alexa Fluor 594 Product Categories: Secondary Antibody Form: Liquid Tested applications: ICC/IF, IHC-F, FC, ELISA Dilution Ratio: IF：1:100-1:1000； IHC：1:500-1:1000；FC：1:500-1:1000；ELISA：1:5000-1:20000 Species reactivity: Mouse Host Species: Goat Conjugation：Alexa Fluor 594 Purity: Affinity purification Immunogen: Mouse IgG |
Storage：
|
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3. |
Services & Support：
|
1、Please do not hesitate to contact us if you have any questions. 2、Please fill in the Technical Support Request Form and email the form to support@yfxbio.com within 3months of receipt of the goods, and we will response to your inquiry within 24 hours. 3、The after-sale service channel will be shut down after 3 months. 4、Producthasnot been fully validated for medical applications. For research use only. |
※ IF=7.7（医学2区，药学）: Yibao Wei，Songjiang Yin，Chen Kuang et al. Casticin promotes M2 macrophage polarisation and dorsal root ganglion neuronal autophagy to alleviate cold hyperalgesia in knee osteoarthritis by regulating histone-lysine N-methyltransferase (SETDB2)Casticin promotes M2 macrophage polarisation and dorsal root ganglion neuronal autophagy to alleviate cold hyperalgesia in knee osteoarthritis by regulating histone-lysine N-methyltransferase (SETDB2). British Journal of Pharmacology, 2026;1–29.
※IF=16(材料科学1区， 纳米科技）：Qin Fan, Jifeng Li, Xinran Qu et al. Selective Depletion of Tumor-Associated Macrophages with Biomineralized Erythrocyte Nanoghosts to Boost Neoadjuvant Radioimmunotherapy. ACS Nano 2026 20 (7), 5561-5576.
